Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation

J Clin Endocrinol Metab. 2017 Mar 1;102(3):893-902. doi: 10.1210/jc.2016-2860.

Abstract

Context: There is much debate surrounding the choice of which patient should be submitted to postsurgical remnant radioiodine remnant ablation (RRA), particularly in low-risk (LR) and intermediate-risk (IR) differentiated thyroid cancer (DTC).

Objective: The aim of this study was to evaluate the role of postoperative high-sensitive thyroglobulin (Tg) on L-thyroxine (LT4-HSTg) and postoperative neck ultrasound (US) in risk restratification and decision to perform RRA.

Patients: We evaluated 505 patients with LR or IR DTC 3 to 4 months after total thyroidectomy (TTx). All patients underwent RRA and a posttherapeutic whole body scan (ptWBS).

Results: After TTx, 29.7% DTC patients had LT4-HSTg <0.1 ng/mL (Group A) and could be restratified as cured: 1 of 150 had lymph node metastases (LN mets) detected by neck US but negative at ptWBS. 56.8% DTC patients had LT4-HSTg between 0.1 and ≤1 ng/mL (Group B) and could be restratified either as cured or not cured. In this group, 15 of 287 (5.2%) had metastases but only 7 were detected by ptWBS; 13.5% DTC patients had LT4-HSTg >1 ng/mL (Group C) and could not be considered as cured by definition. LN mets were present in 11 of 68(16.2%) cases, all detected by neck US. No correlation was found with the presence of metastases and serum LT4-HSTg values or with the level of risk.

Conclusions: LT4-HSTg measured 3 to 4 months after TTx is important in the risk restratification of DTC patients but is less relevant than neck US in the decision to perform RRA.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Autoantibodies / blood*
  • Clinical Decision-Making
  • Female
  • Humans
  • Iodine Radioisotopes / therapeutic use*
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Neck
  • Neoplasm Staging
  • Neoplasms, Multiple Primary / blood
  • Neoplasms, Multiple Primary / diagnostic imaging
  • Neoplasms, Multiple Primary / pathology
  • Neoplasms, Multiple Primary / therapy*
  • Postoperative Period
  • Radionuclide Imaging
  • Radiotherapy, Adjuvant
  • Risk Assessment
  • Thyroglobulin / blood*
  • Thyroid Neoplasms / blood
  • Thyroid Neoplasms / diagnostic imaging
  • Thyroid Neoplasms / pathology
  • Thyroid Neoplasms / therapy*
  • Thyroidectomy*
  • Thyroxine / blood*
  • Tumor Burden
  • Ultrasonography
  • Whole Body Imaging
  • Young Adult

Substances

  • Autoantibodies
  • Iodine Radioisotopes
  • anti-thyroglobulin
  • Thyroglobulin
  • Thyroxine